Medical Equipment Industry Overview

The microneedles drug delivery systems market consists of sales of microneedle drug delivery systems by entities (organizations, sole traders, and partnerships) which allow the users to adapt to a safer alternative process of drug delivery. A microneedles drug delivery system is a device with hundreds of microneedles on a patch that delivers a sufficient amount of drug in treatment. Microneedles drug delivery systems are also known as microneedle patches. The main types of technologies in microneedle drug delivery systems are solid microneedle technology, hollow microneedle technology, dissolved microneedle technology, and others. Peptides are dried on the tips of a microneedles array in the solid microneedles method, which uses a coating of powerful chemicals. The solid microneedles are 250 micrometers to 700 micrometers in length and come in patch form that can be stored at room temperature. The microneedle drug delivery systems are used for drug delivery, vaccine delivery, others and employed in diagnostic laboratories, life sciences, research laboratories, hospitals, ambulatory surgical centers, and others. The global microneedles drug delivery systems market is expected to grow from $0.66 billion in 2020 to $0.75 billion in 2021 at a compound annual growth rate (CAGR) of 13%. The growth in the microneedles drug delivery systems market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The microneedles drug delivery systems market is expected to reach $1.02 billion in 2025 at a CAGR of 8.1%. Increasing research and demand for the vaccination process are predicted to drive the microneedle drug delivery systems market growth. Researchers view microneedles as an alternative way to inject vaccines where the receiver of the vaccine is expected to not feel any sensation of pain. The microneedle patch vaccine was developed initially for flu and measles, however, the technology is now being used increasingly for delivery of the COVID-19 vaccine as well. For instance, in 2020, The University of Connecticut, Vaxess, and Verndari are using microneedles to deliver viral proteins into the skin, where they induce an immune response. According to a Bloomberg report, more than 3.98 billion doses of vaccine have been administered across 180 countries until July 2021. Increased demand from government and health research and development bodies for microneedle drug delivery technology propels the market for microneedle drug delivery systems going forward. Biodegradable microneedle drug delivery patches are increasingly being used in local therapeutic gene delivery and treatment of chronic diseases. The use of biodegradable microneedles patches helps in easy and fast delivery of genes through targeting the skin as a site for local delivery. Gene delivery and treatment with these patches are easily accessible and contain fluid and lymph vessels that help the genetic material to act effectively. For instance, in 2020, a group from Terasaki Institute for Biomedical Innovation has recently worked on optimizing the release and performance of the biodegradable patches. Biodegradable microneedle patches offer several advantages in gene delivery such as improved efficacy, fast delivery, customized delivery, and others. In May 2020, Altaris Capital Partners, a US-based company acquired Kindeva Drug Delivery for $650 million. The deal is expected to help Altaris to develop and provide more innovative drug delivery technologies to the healthcare system by using the expertise of 3M and the Kindeva team. Kindeva Drug Delivery (formerly known as 3M Drug Delivery Systems) is an American manufacturer of pharmaceutical and biotechnology products including inhalation, microneedle, and transdermal drug delivery technologies used for the treatment of cardio and respiratory health conditions. Major players in the microneedle drug delivery systems market are 3M, Zosano Pharma, Becton-Dickinson Technologies, Nanopass Technologies, Corium, Valeritas, Microdermics, TheraJect Inc., LTS Lohmann Therapie-Systeme AG, BioSerenTach (BT), Sorrento Therapeutics, Debiotech, Raphas Co. Ltd., QuadMedicine, SNvia, and NanoBiosciences. North America was the largest region in the microneedles drug delivery systems market in 2020. Europe was the second-largest region in the microneedles drug delivery systems market. The regions covered in the microneedles drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microneedle drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global microneedle drug delivery systems market is segmented - 1) By Technology: Hollow, Porous, Solid, Others 2) By Application: Drug Delivery, Vaccine Delivery, Others 3) By End-User: Diagnostics Laboratories, Life Sciences, Research Laboratories, Hospitals, Ambulatory Surgical Centers, Others

The 3D bioprinting market consists of sales of 3D bioprinting products by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing and utilizing 3D printing to produce biomedical parts that imitate natural tissue characteristics. 3D Bioprinting is a type of additive manufacturing that prints live structures layer by layer, mimicking the behavior of actual living systems, using cells and other biocompatible materials like inks, also known as bio-inks. 3D bioprinting materials are mainly used in connection with drug research and most recently as cell scaffolds to help repair damaged ligaments and joints. The main types of components in 3D bioprinting are 3D bioprinters and bio-inks. 3D bioprinters use three-dimensional technology in combination with biocompatible materials to replicate body parts. It is used for bioprinting of tissue, bone, organs, blood vessels tissue, and biomedical parts. The different types of materials include living cells, hydrogels, extracellular matrices, and others. 3D bioprinting is used in research applications, clinical applications, others and implemented in several verticals such as research organizations and academic institutes, biopharmaceuticals companies, hospitals, others. The global 3D bioprinting market is expected to grow from $771.41 million in 2020 to $933.91 million in 2021 at a compound annual growth rate (CAGR) of 21.1%. The change in growth trend of the 3D bioprinting market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The 3D bioprinting market is expected to reach $1,899.37 million in 2025 at a CAGR of 19.4%. Rising governments and private funding to support 3D bioprinting research activities are expected to drive the growth of the 3D bioprinting market in the forecast period. 3D bioprinting has increasing applications in healthcare, attracting funding from government and private organizations. This funding provides financial and technical assistance across different development phases of 3D bioprinting techniques. For instance, in May 2021, Readily3d SA, a Switzerland-based bioprinting company, received funding of $600,000 from the European Union to develop a living miniature model of the pancreas using its Tomolite 3D bioprinting technique. The Australian Minister for Health funded Curtin University $737,690 in June 2020 to develop and optimize 3D technology for bioprinting skin tissue directly onto model wounds as a prelude to human skin restoration. Furthermore, in January 2020, Aspect Biosystems, a Canada-based 3D bioprinting technology company received a $20 million funding in Series A financing round to advance its technology for 3D bioprinting human tissue which was led by venture capital firm Radical Ventures, Pangaea Ventures, Pallasite Ventures, and Rhino Ventures. Thus, increasing the availability of funding will boost the 3D bioprinting market. Artificial intelligence (AI) is increasingly being used in 3D bioprinting to fabricate bio-tissues in a layer-to-layer fashion from a digital 3D model using a combination of cells, growth factors, and biomaterials. Artificial intelligence is a branch of technology that deals with the simulation of human behavior in machines. AI is used in bioprinting to give suggestions on the best possible printing parameters needed to produce a biocompatible tissue that can fit the patient's physiological makeup by analyzing data and identifying patterns throughout the bioprinting process. For instance, in June 2021, researchers at Queensland University of Technology’s (QUT) Center in Transformative Biomimetics in Bioengineering, and Oregon University integrated AI and machine vision into 3D printers to manufacture customized medical implants. In addition to this, in September 2020, Researchers at Rice University used AI to speed up the development of 3D printed bioscaffolds that help injuries heal. In May 2021, 3D Systems, a US-based company engaged in offering 3D bioprinting technology announced the acquisition of Allevi Inc. for an undisclosed amount. Through this acquisition, 3D Systems plans to utilize Allevi’s expertise to develop applications in the future for the development of human organs in the long term and become a market leader in bioprinting. Allevi Inc. is a US-based company that manufactures 3D bioprinters and bio-inks which are used by researchers. Major players in the 3D bioprinting market are Organovo Holdings Inc., Allevi Inc., Cellink, Aspect Biosystems Ltd., 3D Systems Corporation, Cyfuse Biomedical KK, Envisiontec Inc., Poietis, TeVido BioDevices, Nano3D Biosciences Inc., Digilab Inc., RegenHU, GeSIM GmbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, Stratasys Ltd, ROKIT Healthcare, Inventia Life Science PTY LTD, Vivax Bio LLC, GE Healthcare, and 3D Biotek. North America was the largest region in the 3D bioprinting market in 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the 3D bioprinting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global 3D bioprinting market is segmented - 1) By Component: 3D Bioprinters, Bioinks 2) By Material: Living Cells, Hydrogels, Extracellular Matrices, Others 3) By Application: Research Applications, Clinical Application, Others 4) By End User: Research Organization And Academic Institutes, Biopharmaceuticals Companies, Hospitals, Others

The digital therapeutics market consists of sales of digital therapeutics devices and software by entities (organizations, sole traders, and partnerships) that are used in the treatment of medical disorders or diseases. Digital therapeutics (DTx) are the products that give evidence-based therapeutic treatments to patients through high-quality software applications in order to prevent, manage, or treat a medical ailment or disease. Various applications and tracking devices are integrated into digital therapies for the control and cure of medical disorders. Connected devices such as insulin pumps, blood glucose meters, and wearable gadgets communicate data to a centralized system in digital therapeutics. The main product types of digital therapeutics are devices and software. Digital therapeutics devices provide intervention to prevent, manage or treat a disease or medical disorder. This includes devices such as sensors used to track medication usage and location data. The different sales channels include business-to-business (B2B), business-to-consumer (B2C). Digital therapeutics are used in preventive applications and treatment or care-related applications. The global digital therapeutics market is expected to grow from $3.53 billion in 2020 to $4.20 billion in 2021 at a compound annual growth rate (CAGR) of 19%. The change in growth trend of the digital therapeutics market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The digital therapeutics market is expected to reach $10.62 billion in 2025 at a CAGR of 26.1%. The increasing use of smartphones and tablets coupled with healthcare apps is expected to propel the growth of the digital therapeutics market in the forecast period. Smartphones and tablet-based healthcare apps have numerous advantages over the lower rate of medication errors, facilitating preventive care, and more accurate staffing. For instance, according to the Groupe Speciale Mobile Association (GSMA) report, globally 2.71 billion people owned a smartphone in 2019 and the number of smartphone users in the US reached 270 million in 2020. Therefore, the increasing use of smartphones drives the growth of the digital therapeutics market. Technological innovation is an emerging trend gaining popularity in the digital therapeutics market. Major companies operating in the market are focused on developing technologically advanced solutions for digital therapeutics to strengthen their position. For instance, in 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Click Pharmaceuticals, a US-based prescription digital therapeutics business, have agreed to collaborate on the development and commercialization of a digital medication for schizophrenia patients worth more than $500 million. The treatment named CT-155 will be a mobile app developed on Click's technology platform, according to the company. In April 2020, Novartis, a Switzerland-based pharmaceutical company acquired Ambylotech for an undisclosed amount. This acquisition is expected to help Novartis to develop Amblyotech's novel digital technology to treat amblyopia or lazy eye through digital therapeutics. Amblyotech is a US-based digital therapeutics company. Major players in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Livongo Health, Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Mango Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic Plc., Teladoc Health Inc, and Fitbit Health Solutions. North America was the largest region in the digital therapeutics market in 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global digital therapeutics market is segmented - 1) By Product: Software, Devices 2) By Sales Channel: Business-To-Business (B2B), Business-To-Consumer (B2C) 3) By Application: Preventive Applications, Treatment Or Care-Related Applications

The oxygen concentrators market consists of sales of oxygen concentrators devices by entities (organizations, sole traders, and partnerships) which refers to medical devices used for supplying oxygen to patients suffering from respiratory diseases. The oxygen concentrator separates nitrogen and oxygen from the air in the environment and provides pure oxygen to the patient. There is no need for constant refilling for an oxygen concentrator as it draws oxygen from the surrounding air. The main types of oxygen concentrators are portable and stationary. Portable oxygen concentrators are smaller, more mobile, affordable, and can be easily moved from one place to another. The different technologies include pulse dose, continuous flow, and others. These oxygen concentrators are used for supplying oxygen for patients suffering from chronic obstructive pulmonary disease (COPD), lung cancer, pneumonia, other respiratory system diseases and are used by hospitals, home care, others. The global oxygen concentrators market is expected to grow from $1.92 billion in 2020 to $2.16 billion in 2021 at a compound annual growth rate (CAGR) of 12.7%. The change in growth trend of the oxygen concentrators market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The oxygen concentrators market is expected to reach $2.92 billion in 2025 at a CAGR of 7.8%. The increase in the prevalence of respiratory disorders across the globe contributes to the growth of the oxygen concentrators market. Globally, asthma and chronic obstructive pulmonary disease (COPD) are the most common chronic respiratory diseases. According to the Forum of International Respiratory Societies (FIRS), 384 million people suffer from COPD and 3 million people die every year. According to the Centers for Disease Control and Prevention’s National Health Interview Survey, in 2019 in the USA, 4.6% of adults had suffered from COPD, emphysema, or chronic bronchitis. Respiratory disorders need the additional flow of oxygen. The oxygen concentrator provides the required oxygen by producing it from the environment. Therefore, the increase in the prevalence of respiratory disorders is driving the growth of the oxygen concentrators market. Companies in the oxygen concentrators market are increasingly investing in technologies such as artificial intelligence and low-cost portable devices to improve the functionality of these oxygen concentrators. There has been a growing demand for portable, low-cost concentrators owing to the pandemic. For instance, in March 2021, a team of researchers at MIT’s Electrochemical Energy Lab (EEL) launched a low-cost portable concentrator that can be adopted in places with limited infrastructure and high demand. The companies such as Servotech Power Systems, an India-based manufacturer of LED lights and solar products is manufacturing the noiseless, lightweight, and portable oxygen concentrator equipment that provides a constant flow of oxygen and can be easily adjusted to meet the needs of the patient. In May 2021, OxyGo LLC, a manufacturer of portable oxygen concentrators acquired LIFE Corporation for an undisclosed amount. Through this acquisition, OxyGo can offer services to compressed gas users, and the company can also expand its oxygen expertise by providing better products and services using LIFE corporation expertise. LIFE Corporation is an India-based company that manufactures portable emergency oxygen and CPR administration equipment. Major players in the oxygen concentrators market are Koninklijke Philips N.V., Invacare Corporation, DeVilbiss Healthcare LLC, Nidek Medical, Inogen, O2 Concepts, Teijin Limited, Supera Anesthesia Innovations, GCE Group, CAIRE Inc., Precision Medical Inc., ResMed, Linde, Longfian Scitech, and OxyGo. North America was the largest region in the oxygen concentrators market in 2020. Europe was the second-largest region in the oxygen concentrator market. The regions covered in the oxygen concentrators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oxygen concentrators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global oxygen concentrators market is segmented - 1) By Type: Portable, Stationary 2) By Technology: Pulse Dose, Continuous Flow, Others 3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer, Pneumonia, Others 4) By End User: Hospitals, Home Care, Others

The gastrointestinal bleeding treatment devices market consists of sales of gastrointestinal bleeding treatment devices and equipment for gastrointestinal bleeding. Gastrointestinal (GI) bleeding is a sign of an illness in which the gastrointestinal system bleeds. The bleeding could occur anywhere in the gastrointestinal system, including the large intestine, anus, esophagus, small intestine, rectum, and stomach. This GI bleeding can be caused by hemorrhoids, peptic ulcers, tears or inflammation in the esophagus, diverticulosis and diverticulitis, ulcerative colitis and Crohn's disease, colonic polyps, or cancer in the colon, stomach, or esophagus.

The main type of products used in gastrointestinal bleeding treatment devices market are endoscopic mechanical devices, endoscopic thermal devices, and others. Endoscopic mechanical devices are used in the management of GI arterial bleeding. These include hemostatic clips, also known as through-the-scope (TTS) clips, endoscopic detachable snare ligation (EDSL) devices, endoscopic suturing, over-the-scope clips (OTSC) and will be reviewed for their technology use and clinical application. The gastrointestinal bleeding treatment devices market is also segmented by GI tract division into the lower GI tract and upper GI tract and is used in hospitals or clinics, ambulatory surgical centers, others.

The global gastrointestinal bleeding treatment devices market is expected to grow from $682.30 million in 2020 to $722.37 million in 2021 at a compound annual growth rate (CAGR) of 5.9%. The growth in the gastrointestinal bleeding treatment devices market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The gastrointestinal bleeding treatment devices market is expected to reach $889.11 million in 2025 at a CAGR of 5.3%.

The rise in the incidences of upper gastrointestinal bleeding is likely to contribute to the growth of the gastrointestinal bleeding treatment devices market during the forecast period. The upper gastrointestinal (GI) bleeding occurs in the esophagus, the stomach, or the upper part of the small intestine and can be caused due to peptic ulcers, esophagitis, enteritis, gastritis, cancer, and other reasons. For instance, according to the National Institute for Health and Care Excellence, in the UK the incidence of acute upper GI bleeding ranges from 84-172 per 100,000 of the population per year. Furthermore, as per the study published by the International Journal of Surgery Global Health in May 2020, the incidence of acute upper GI bleeding in the Western world recorded to be 103 cases per 100,000 adults annually. Therefore, the rise in the incidences of upper gastrointestinal bleeding propels the growth of the gastrointestinal bleeding treatment devices market.

The increasing product approvals are the key trend gaining popularity in the gastrointestinal bleeding treatment devices market. Key players in the market are focusing on product approvals to maintain a comparative advantage over competitors in the industry. For example, in February 2021, EndoClot Plus Inc., a US-based company developing medical devices to meet the needs of the GI professional announced U.S. Food and Drug Administration (FDA) approval for EndoClot Polysaccharide Hemostatic System (EndoClot PHS), which is an advanced product that will assist Gastroenterologists in stopping bleeding quickly and effectively. EndoClot PHS is a one-time-use device that consists of a starch-based powder hemostat that is applied directly to the bleeding location using a flexible endoscope.

In January 2021, Olympus Corporation, a Japan-based company offering solutions for effective treatment of gastrointestinal bleeding announced a collaboration with Hitachi Ltd for a five-year period. Under this collaboration, the companies will work together to develop Endoscopic Ultrasound Systems (EUS), which are used to treat digestive diseases and assess the stage of cancer in the bronchus, liver, pancreas as well as in minimally invasive care, thereby contributing to medical treatment. Hitachi Ltd is a Japanese multinational conglomerate company offering gastrointestinal diagnoses solutions.

Major players in the gastrointestinal bleeding treatment devices market are CONMED, Boston Scientific Corporation, US Medical Innovations, Ovesco Endoscopy AG, Olympus Corporation, Cook Medical, Erbe Elektromedizin GmbH, Steris Plc, and Pfizer Inc.

North America was the largest region in the gastrointestinal bleeding treatment devices market in 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal bleeding treatment devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the gastrointestinal bleeding treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global gastrointestinal bleeding treatment devices market is segmented -

1) By Product: Endoscopic Thermal Devices, Others

2) By GI Tract Division: Upper GI Tract, Lower GI Tract

3) By End User: Hospitals Or Clinics, Ambulatory Surgical Centers, Others

The medical tricorder market consists of sales of medical tricorder devices by entities (organizations, sole traders, and partnerships) that come with a detachable, high-resolution hand-held scanner that transmits vital signs data to the tricorder. A medical tricorder is a handheld scanning gadget that enables users to diagnose medical problems and collect basic vital signs in seconds.

The main types of the medical tricorder are USB camera, fiber optics camera, wireless, corded, others. A USB camera is a type of medical tricorder that allows users to record high-quality video with a fiberscope camera. The applications of medical tricorder include diagnosis, monitoring, others and are used in various sectors such as hospitals, clinics, and others.

The global medical tricorder market is expected to grow from $3.33 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 12.7%. The change in growth trend in the medical tricorder market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The medical tricorder market is expected to reach $5.34 billion in 2025 at a CAGR of 9.2%.

The increase in the number of chronic illnesses such as cardiovascular diseases and diabetes is contributing to the growth of the medical tricorder market. Chronic diseases are illnesses that endure for a year or longer and require ongoing medical care, interfere with daily activities, or both. Chronic diseases such as cardiovascular disease, cancer, and diabetes are among the world's top causes of mortality and disability. Medical tricorders are used to diagnose and detect diabetes, cardiovascular diseases, and other chronic illnesses. According to the Physician's Academy for Cardiovascular Education, in 2019, 523 million cardiovascular cases were registered globally. Moreover, according to the World Health Organization (WHO), in 2019 around 17.9 million or 32% of all global deaths are due to cardiovascular diseases.

The growing technological advancement is a key trend gaining popularity in the medical tricorder market. Major companies operating in the medical tricorder market focused on developing technological solutions for medical tricorder devices to strengthen their position. For instance, in May 2020, Apple, a US-based technology company has bought the medical tricorder closer to reality by using AR technology through Butterfly Network, a US-based digital health company. Pregnancies, possibly fractured bones, and even lung diseases are the features of the Butterfly Network. Doctors are currently using the technology to screen for evidence of COVID-19-related lung damage remotely.

In June 2020, Healthy.io, an Israel-based developer of smartphone urinalysis tech, has acquired Inui Health for $9 million. The acquisition of Inui Health supports Healthy.io to enter into the US market. The company also aims to move into pregnancy monitoring to detect possible complications. Inui Health, formerly known as Scanadu is a US-based medical diagnostics company that offers medical tricorders.

Major players in the medical tricorder market are QuantuMDx, Cloud DX, Qualcomm Technologies, Basil Leaf Technologies, Healthy.io Ltd., Ionis Pharmaceutical, Fujikura, Basler, and Hamamatsu Photonics.

North America was the largest region in the medical tricorder market in 2020. Europe was the second-largest market in the medical tricorder market. The regions covered in the medical tricorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the medical tricorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global medical tricorder market is segmented -

1) By Type: USB Camera, Fiber Optic Camera, Wireless, Corded, Others

2) By Application: Diagnosis, Monitoring, Others

3) By End User: Hospitals, Clinics, Others

Dialysis Devices and Equipment Market Definition

The dialysis devices and equipment market consists of the sale of dialysis devices and equipment and related services by entities (organizations, sole traders and partnerships) that manufacture dialysis devices and equipment which are used in the treatment of dialysis patients. The dialysis devices and equipment industry includes establishments that manufacture dialysis devices and equipment such as dialyzers and dialysis pumping machines and other instruments used in the dialysis process, including blood pumps, catheters and tubing kits. Dialysis devices and equipment are used in the dialysis process to filter the patient’s blood, in order to remove waste products such as urea, creatinine and excess water, such impurities usually occur when the kidneys fail or are damaged. Dialysis allows patients with kidney failure a chance to live productive lives. There are three types of dialysis – hemodialysis dialysis, peritoneal dialysis and continuous renal replacement.

Drug Delivery Devices Market Definition

The drug delivery devices market consists of the sales of medical devices and equipment that are used for delivering drugs to a specific part of the body to treat diseases such as cancer, respiratory diseases, diabetes, and cardiovascular diseases and to treat and prevent infectious diseases. The market includes the sales of devices that are specifically made for delivering drugs according to the various administration techniques such as oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Drug delivery devices are used in various patient care settings such as hospitals, diagnostic centers, pharmaceutical companies, clinics, and home care settings are included in this market. Drug delivery devices are engineered technologies that offer targeted and controlled release of therapeutic agents. These devices are specially designed for the delivery of a drug or therapeutic agent via a specific route of administration such as oral drug delivery, injectable drug delivery, and nasal drug delivery, among others. Some drug delivery devices help in simplifying drug delivery for patients and practitioners and include special features designed to ease self-dosing and encourage patient adherence with novel regimens.